Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 5/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.63 |
| ▸ | TMIGD3 | P0DMS9 | 6/20 | 0.63 |
| ▸ | HTR2B | P41595 | 5/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573481 | 0.93 | ADORA3 (0.70) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL26969054 | 0.86 | ADORA3 (0.70) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29575011 | 0.86 | ADORA3 (0.70) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29573850 | 0.84 | ADORA3 (0.63) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29573869 | 0.84 | HRH2 (0.52) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29573830 | 0.83 | ADORA3 (0.62) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29573284 | 0.83 | ADORA3 (0.62) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29574083 | 0.82 | ADORA3 (0.63) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29574049 | 0.80 | ADORA3 (0.72) | HSP90B1ADORA3TMIGD3HTR2BADORA1 | |
| SCHEMBL29573468 | 0.80 | HTR2B (0.47) | HSP90B1ADORA3TMIGD3HTR2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |